IGF2BP3 and metastatic malignant neoplasm in the lymph nodes: When the mutation is a THADA/IGF2BP3 fusion, the surgeon might be less inclined to perform this lymph node exploration because they are aware that the likelihood of lymph node metastases is significantly less.